Navigation Links
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
Date:6/7/2009

t recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery and acid stomach. Nausea is the most common side effect when first starting BYETTA, but decreases over time in most patients.

If patients experience the following severe and persistent symptoms (alone or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should talk to their healthcare provider because these symptoms could be signs of serious medical conditions. BYETTA may reduce appetite, the amount of food eaten, and body weight. No changes in dose are needed for these side effects. These are not all of the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For full prescribing information, visit www.BYETTA.com.

About Amylin, Lilly and Alkermes

Amylin, Lilly, and Alkermes are working together to develop exenatide once weekly, a subcutaneous injection of exenatide for the treatment of type 2 diabetes based on Alkermes' proprietary technology for long-acting medications. Exenatide once weekly is not currently approved by any regulatory agencies.

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
2. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
3. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
6. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
7. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
8. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
9. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... SOUTH PLAINFIELD, N.J. , Sept. 4, 2015 ... is pleased to announce five recipients of its ... to Realize Innovation, Vision and Empowerment), designed to ... the Duchenne muscular dystrophy (DMD) community. The announcement ... for the international World Duchenne Awareness Day on ...
(Date:9/4/2015)... Future Prospects for Companies in ... Rhinitis drugs - new study showing you trends, ... market for allergic rhinitis drugs heading? What are the ... report shows you potential revenues and other trends to ... 326 page report provides 273 tables, charts, and graphs. ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... , EXTON, Pa., Oct. 9 Kensey Nash ... release its earnings results for its first quarter ended September ... 22, 2009. , Joe Kaufmann, President and CEO, ... Thursday, October 22, 2009 at 9:00 A.M. Eastern Time. ...
... 9 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... announced sale of shares of its Series D convertible ... institutional investors, representing gross proceeds to ADVENTRX of approximately ... from the offering to fund its operations during the ...
Cached Medicine Technology:Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts ... the Year” awards at this year’s Microsoft Worldwide Partner Conference that was held ... the Year” Award Winner for Data Platform services, the 2015 HP and Microsoft ...
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... Amini, announces that CEREC technology is now available at CitiDent. CEREC is a ... machinery. In addition to saving time for patients by eliminating the need for ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Mike Day, a ... 2007, will compete in the Ironman World Championships in Kona on October 10th. , ... incurred Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments that restore their ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a ... announced its only mission and research focus: Water Life Science®. In the current ... water evaporation is becoming dangerously accelerated. As a result of the global fresh ...
(Date:9/4/2015)... ME (PRWEB) , ... September 04, 2015 , ... ... focus on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at ... , Speakers at the 2015 symposium are doctors and researchers at the top ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... 22-hour procedure replaced 80% of severely disfigured woman,s face, ... A team of eight Cleveland Clinic surgeons has completed ... most of the woman,s face, including about 80 percent ... most of the sinuses, upper jaw -- essentially ...
... Calif., Dec. 17 Human Pheromone,Sciences, Inc. (OTC Bulletin ... filed a Comprehensive Patent Application with the U.S. Patent ... previously undeveloped,compound with its origin in sea coral, which ... feelings of positive social relationships,personal well-being and social attraction. ...
... LLC today announced positive results from a Phase 2 ... Multiple Sclerosis patients with documented cognitive dysfunction. , ... study, Cognition Pharmaceuticals reported, the active group obtained significantly ... learning, including the Brief Visuospatial Memory Test - Revised, ...
... Jude Children,s Research Hospital have answered a central question ... rise to tumors. Stem cells are immature cells that ... cells that compose the range of body tissues. In ... arise from mutant forms of stem cells. , ...
... Dec. 17 Time Life is proud to announce they have teamed ... a brand new fitness program set to dance hits of the ,70s, ... , Cheryl Burke has been dancing since the age ... titles around the world. For the past six television seasons, the ...
... Mass., Dec. 17 Hologic, Inc. (Nasdaq: HOLX ... medical imaging systems and surgical products dedicated to serving the ... first quarter fiscal 2009 operating results on Monday, February 2, ... will host a conference call on Monday, February 2, 2009 ...
Cached Medicine News:Health News:Doctors Describe First U.S. Face Transplant 2Health News:Doctors Describe First U.S. Face Transplant 3Health News:Doctors Describe First U.S. Face Transplant 4Health News:HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis 2Health News:Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis 3Health News:Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis 4Health News:Molecular marker identifies normal stem cells as intestinal tumor source 2Health News:Cheryl Burke of 'Dancing with the Stars' Joins Forces With Time Life To Create a Brand New Dance Workout, 'DISCO ABS' 2Health News:Cheryl Burke of 'Dancing with the Stars' Joins Forces With Time Life To Create a Brand New Dance Workout, 'DISCO ABS' 3Health News:Hologic, Inc. to Release First Quarter Fiscal 2009 Operating Results on Monday, February 2, 2009 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: